If this is a forwarded email, subscribe now to receive future updates on this topic. |
|---|
You are subscribed to one or more CDC code set email subscription services. Subscription links are available on each of the pages below. Vaccine Code Set Update Publication Date: December 19, 2024
The individual filenames included in this distribution contain the publication date (20241219)
|
|---|
Release Notes: This release includes updates for all vaccine codes. It does not include updates for Vaccine Information Statement (VIS) related codes. General note regarding this release: Codes with “Last Update” dates after October 23, 2024, and before December 19, 2024, reflect the changes and additions in this release. This release includes vaccine code set updates related to the following: - Vaccine Manufacturer VBI cessation of operations, voluntary recall PreHevbrio® Hepatitis B (HepB) vaccine. The codes have been updated to reflect this recall.
- Hepatitis B vaccine code updates have been made for Engerix-B® and Recombivax HB® vaccines. Codes will more accurately reflect mappings of NDCs to CPT and CVX codes.
- CPT mappings have been updated for the dengue fever vaccine (Dengvaxia®) NDC and CVX codes.
- Vaccine code retirements have been finalized for the zoster live vaccine (Zostavax®) and the diphtheria and tetanus toxoids vaccine (DT/Sanofi).
- Other code updates.
Detailed release notes will be provided upon publication. You may subscribe to receive email vaccine code set notifications and release notes here Vaccine Data Code Sets | Immunization Information Systems (IIS) | CDC. Vaccine Code Set Updates – Details 1. Vaccine Manufacturer VBI Cessation of Operations, Voluntary Recall PreHevbrio® Hepatitis B (HepB) Vaccine The vaccine manufacturer VBI Vaccines Inc. (VBI) has ceased operations effective 11/15/2024. VBI has called for a voluntary nationwide recall of PreHevbrio® Hepatitis B (HepB) vaccine. The CDC statement below includes a link to the VBI recall announcement. In addition to the statement below, additional guidance regarding HepB vaccine administration and dosing can be found here Hepatitis B Vaccine Administration | Hepatitis B | CDC. Voluntary Nationwide Recall
The vaccine manufacturer is initiating a voluntary nationwide recall of all remaining PreHevbrio® [Hepatitis B Vaccine (Recombinant) NDC 75052-001-10] due to restructuring of the company and discontinuing operations. Further distribution or use of any remaining PreHevbrio vaccine by healthcare providers or others should cease immediately. Vaccine code set records relating to VBI and PreHevbrio® have been updated as follows: - NDCs for Unit of Sale (UoS) 75052-001-10 and Unit of Use (UoU) 75052-001-01 have had the end date set to 11/15/2024.
- MVX code “VBI” has been retired and note field updated to reflect the above.
- Tradename product record for PreHevbrio® has been retired and note field updated to reflect the 11/15/2024 recall.
- CVX code “220” remains in active status. The note field has been updated to reflect the recent recall. CVX code “220” will be retired at a later date as the product might continue to be administered from existing inventories for a transitional period of time.
2. HepB Vaccine Code Mapping and Other Updates for Engerix-B® and Recombivax HB® During summer of 2024, CDC added NDC mapping to CPT codes in addition to the existing CPT to CVX code map. These NDC UoU to CPT maps appear on the new NDC Consolidated Crosswalk Lookup table, which can be found here IIS | Code Sets | NDC | Vaccines | CDC. The more granular NDC level CPT mapping can be more accurate in the uncommon cases where there are multiple CPT codes available that are specifically applicable only to specific NDCs or dosage regimen. These CPTs were previously not mapped, or only mapped to the higher level CVX code. The Engerix-B® and Recombivax HB® vaccines represent vaccines where highly specific CPT codes may apply. We have performed an analysis of the NDCs and their CVX and NDC mappings and have made updates as needed to the existing maps. In addition, minor updates were made to the associated CVX codes. This analysis has resulted in three distinct areas of change: - Minor HepB CVX code updates to the CVX descriptions and note fields
- Updates to the CPT to CVX map
- Updates to the NDC UoU maps including; UoU NDC to CVX code and UoU NDC to CPT code.
The details of each of the above changes are as follows: - Minor HepB CVX code updates to the CVX Descriptions and Note fields. The following CVX codes had updates related to the overall review of Engerix-B® and Recombivax HB® vaccine coding.
CVX Code | Long Description | Short Description | Note (*) |
|---|
08 | hepatitis B vaccine, pediatric or pediatric/adolescent dosage | Hep B, adolescent or pediatric | This code applies to any standard pediatric formulation of Hepatitis B vaccine. It should not be used for the 2-dose hepatitis B schedule for adolescents (11-15 year olds). It requires Merck's Recombivax HB adult formulation. Use code 43 for that vaccine. |
|---|
43 | hepatitis B vaccine, adult dosage | Hep B, adult | This code applies to any standard adult dose and schedule. Also use CVX 43 for the FDA approved Recombivax HB 2-dose hepatitis B schedule for adolescents (11-15 year olds) using the adult formulation. |
|---|
44 (**) | Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient | Hep B, high-dosage, dialysis or IC | This code is used record patient high dosage vaccine administration for dialysis or immunocompromised patients. For NDCs that are used for both regular vaccine and dialysis/IC high-dosage schedules (e.g. Engerix-B), are mapped to both CVX 43 and CVX 44. CVX code 44 should be utilized to record dialysis/IC dosing. |
|---|
(*) Note fields for all three CVX codes above were updated for clarity.
(**) CVX code 44 Long and Short Descriptions were updated for more accurate representation along with the note field. - Updates to the CPT to CVX map. After detailed review, the following are the updated CPT to CVX maps:
CPT Code | Mapped to CVX Code |
|---|
CPT Code | CPT Description | CVX Code | CVX Short Description | CVX Long Description |
|---|
90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | 08 | Hep B, adolescent or pediatric | hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
|---|
90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use |
|---|
90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | 43 | Hep B, adult | hepatitis B vaccine, adult dosage |
|---|
90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
90740 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use | 44 | Hep B, high-dosage, dialysis or IC | Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient |
|---|
90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use |
|---|
- Updates to the NDC UoU maps including: UoU NDC to CVX code and UoU NDC to CPT code. The following table provides the updated UoU NDC mappings for each associated NDC UoS/UoU pair.
NDC to CVX and CPT Mapping |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme LLC |
|---|
Unit of Sale
NDC10, NDC11 | Unit of Use
NDC10, NDC 11 | Use Unit Presentation | NDC Dose/Target Population | UoU to CVX | CVX Short Name | UoU to CPT | CPT Description |
|---|
0006-4093-02
00006-4093-02 | 0006-4093-01
00006-4093-01 | SYRINGE | Pediatric 0.5mL dose | 08 | Hep B, adolescent or pediatric | 90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use |
|---|
0006-4981-00
00006-4981-00 | 0006-4981-01
00006-4981-01 | VIAL, SINGLE-DOSE | Pediatric 0.5mL dose | 08 | Hep B, adolescent or pediatric | 90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use |
|---|
0006-4094-02
0006-4094-020 | 0006-4094-01
00006-4094-01 | SYRINGE | Adult 1mL (3 dose sched) + Adolescent 2 dose sched using adult 1 mL dose | 43 | Hep B, adult | 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use |
|---|
0006-4995-00
00006-4995-00 | 0006-4995-01
00006-4995-01 | VIAL, SINGLE-DOSE | Adult 1mL (3 dose sched) + Adolescent 2 dose sched using adult 1 mL dose | 43 | Hep B, adult | 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use |
|---|
0006-4992-00
00006-4992-00 | 0006-4992-01
00006-4992-01 | VIAL, SINGLE-DOSE | Adult 1 mL high-dose for dialysis and IC | 44 | Hep B, high-dosage, dialysis or IC | 90740 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use |
|---|
ENGERIX-B | GlaxoSmithKline Biologicals SA |
|---|
58160-820-52
58160-0820-52 | 58160-820-43
58160-0820-43 | SYRINGE | Pediatric 0.5mL dose | 08 | Hep B, adolescent or pediatric | 90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use |
|---|
58160-821-11
58160-0821-11 | 58160-821-01
58160-0821-01 | VIAL | Adult dose 1mL (3 dose sched) + dialysis/IC (4 dose sched) | 43 | Hep B, adult | 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
44 | Hep B, high-dosage, dialysis or IC | 90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use |
|---|
58160-821-34
58160-0821-34 | 58160-821-05
58160-0821-05 | SYRINGE | Adult dose 1mL (3 dose sched) + dialysis/IC (4 dose sched) | 43 | Hep B, adult | 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
44 | Hep B, high-dosage, dialysis or IC | 90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use |
|---|
58160-821-52
58160-0821-52 | 58160-821-43
58160-0821-43 | SYRINGE | Adult dose 1mL (3 dose sched) + dialysis/IC (4 dose sched) | 43 | Hep B, adult | 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use |
|---|
44 | Hep B, high-dosage, dialysis or IC | 90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use |
|---|
3. CPT mappings have been updated for the dengue fever vaccine (Dengvaxia®) NDC and CVX codes. - CPT to CVX map has been added. Note that the Dengvaxia® product tradename identifies it as a tetravalent vaccine. However, the formulation described in DailyMed indicates there are four identified antigen strains. Thus, it may also be considered quadrivalent for purposes of vaccine coding and mapping. The CPT to CVX map has been updated as follows:
CPT Code | CPT Description | CVX Code | CVX Short Description |
|---|
90587 | Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use | 56 | dengue fever tetravalent |
|---|
- Dengvaxia® NDC UoU to CPT map has been updated as follows:
Sale Proprietary Name | Sale Labeler | Sale NDC1, NDC11 | Use NDC10, NDC11 | UoU to CPT | CPT Long Description |
|---|
Dengvaxia® | Sanofi Pasteur, Inc | 49281-605-01
49281-0605-01 | 49281-606-58
49281-0606-58 | 90587 | Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use |
|---|
4. Vaccine code retirements have been finalized for the zoster live vaccine (Zostavax®) and the diphtheria and tetanus toxoids vaccine (DT/Sanofi). - Zostavax® NDCs previously retired effective Fall of 2022. Associated CVX code 121, “zoster vaccine, live” status changed to “Inactive” and CVX note field updated. Product table record “ZOSTAVAX” has been retired and Product note field updated.
- DIPHTHERIA AND TETANUS TOXOIDS ADSORBED (DT), Sanofi Pasteur, Inc. The following DT vaccine UoS and UoU NDCs have been retired and end dates added of 04/30/2023. In addition, Product table record “DT(GENERIC)” status has been set to retired and the Product note field has been updated. CVX code 28, “diphtheria and tetanus toxoids, adsorbed for pediatric use” status has been changed to “Inactive” and the CVX note field has been updated.
Unit of Sale
NDC10, NDC11 | Unit of Use
NDC10, NDC11 |
|---|
49281-225-10
49281-0225-10 | 49281-225-58
49281-0225-58 |
|---|
5. Other code updates. - A new NDC UoS/UoU pair for a carton of 2 syringes has been added for the Moderna Respiratory Syncytial Virus (RSV) vaccine, mRESVIA® as follows:
Unit of Sale
NDC10, NDC11 | Unit of Use
NDC10, NDC11 |
|---|
80777-345-89
80777-0345-89 | 80777-345-01
80777-0345-01 |
|---|
|
|---|
Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348
Questions or Problems | |
|---|
|
|---|
|
